Clinical Report: ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Overview

The ASCENT-04 study presented by Dr. Sara Tolaney demonstrated that patients receiving sacituzumab govitecan plus pembrolizumab as first-line therapy had longer progression-free survival compared to standard therapy.

Background

The treatment landscape for metastatic triple-negative breast cancer (mTNBC) has evolved, with immune checkpoint inhibitors becoming standard for PD-L1 positive cases. The ASCENT-04 study provides insights into the efficacy of sacituzumab govitecan in combination with pembrolizumab.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

• Patients receiving sacituzumab govitecan plus pembrolizumab had longer progression-free survival compared to standard therapy.
• The analysis was based on biomarker subgroups within the ASCENT-04 study.
• The study supports the use of sacituzumab govitecan as a first-line treatment for PD-L1 positive mTNBC.

Clinical Implications

The findings from the ASCENT-04 study suggest that sacituzumab govitecan in combination with pembrolizumab may be a viable first-line treatment option for patients with PD-L1 positive mTNBC.

Conclusion

The ASCENT-04 study highlights the benefits of sacituzumab govitecan plus pembrolizumab in patients with metastatic triple-negative breast cancer.

Related Resources & Content

1. FDA, FDA, 2026 -- FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
2. Sara Tolaney, MD, MPH, Journal of Clinical Oncology, 2026 -- ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in participants with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC)
3. dana-farber — ASCO26: Sara Tolaney, MD, MPH, ASCENT-03
4. dana-farber — ASCENT-03 Study Presented by Sara Tolaney, MD, MPH
5. dana-farber — ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD
6. dana-farber — SABCS 2022: Sara Tolaney, MD, MPH
7. ASCO26: Sara Tolaney, MD, MPH, ASCENT-03
8. ASCENT-03 Study Presented by Sara Tolaney, MD, MPH
9. ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD
10. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer | FDA
11. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer | New England Journal of Medicine
12. ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC). | Journal of Clinical Oncology